All In Biotech

Drug Trial Radar · NCT01061736

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients

A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy

Last checked: Nov 20, 2026Latest source record: Jun 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,675 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,675

Actual

Start

Mar 2010

Primary completion

Oct 2013

Study completion Oct 2013

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Feb 3, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objectives: Part A (dose ranging study): To demonstrate that sarilumab (SAR153191/REGN88) on top of MTX was effective on reduction of signs and symptoms of rheumatoid arthritis at 12 weeks. Part B (pivotal study): To demonstrate that sarilumab added to MTX was effective in: * reduction of signs and symptoms of rheumatoid arthritis at 24 weeks * inhibition of progression of structural damage at 52 weeks * improvement in physical function at 16 weeks Secondary Objectives: Part B: To demonstrate that sarilumab added to MTX was effective in induction of a major clinical response at 52 weeks To assess the safety of sarilumab added to MTX To document the pharmacokinetic profile of sarilumab added to MTX in participants with active rheumatoid arthritis who were inadequate responders to MTX therapy.

Conditions

  • Rheumatoid Arthritis

Interventions

  • SarilumabDrug

    Pharmaceutical form: solution for injection Route of administration: subcutaneous

  • Placebo (for sarilumab)Drug

    Pharmaceutical form: solution for injection Route of administration: subcutaneous

  • MethotrexateDrug

    Same weekly dose as received prior to enrollment

  • Folic AcidDrug

    According to local standard

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12Time frame: Baseline to Week 12
  2. Part B: Percentage of Participants Achieving ACR20 Response at Week 24Time frame: Baseline to Week 24
  3. Part B: Change From Baseline in Health Assessment Question Disability Index (HAQ-DI) at Week 16Time frame: Baseline, Week 16
  4. Part B: Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 52Time frame: Baseline, Week 52

Locations

262 sites in 36 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840070

    Anniston, Alabama

  • Investigational Site Number 840004

    Birmingham, Alabama

  • Investigational Site Number 840072

    Gilbert, Arizona

  • Investigational Site Number 840029

    Beverly Hills, California

  • Investigational Site Number 840007

    Palm Desert, California

  • Investigational Site Number 840008

    San Francisco, California

  • Investigational Site Number 840021

    Santa Maria, California

  • Investigational Site Number 840049

    Upland, California

  • Investigational Site Number 840050

    Dunedin, Florida

  • Investigational Site Number 840041

    Jacksonville, Florida

  • Investigational Site Number 840067

    Jupiter, Florida

  • Investigational Site Number 840048

    Miami, Florida

  • Investigational Site Number 840006

    Orlando, Florida

  • Investigational Site Number 840063

    Palm Harbor, Florida

  • Investigational Site Number 840060

    Sarasota, Florida

  • Investigational Site Number 840003

    Atlanta, Georgia

  • Investigational Site Number 840028

    Decatur, Georgia

  • Investigational Site Number 840027

    Marietta, Georgia

  • Investigational Site Number 840018

    Idaho Falls, Idaho

  • Investigational Site Number 840046

    Chicago, Illinois

  • Investigational Site Number 840015

    Lexington, Kentucky

  • Investigational Site Number 840073

    Cumberland, Maryland

  • Investigational Site Number 840055

    Frederick, Maryland

  • Investigational Site Number 840013

    Wheaton, Maryland

  • Investigational Site Number 840066

    St Louis, Missouri

  • Investigational Site Number 840071

    Omaha, Nebraska

  • Investigational Site Number 840056

    New York, New York

  • Investigational Site Number 840068

    Hickory, North Carolina

  • Investigational Site Number 840044

    Toledo, Ohio

  • Investigational Site Number 840002

    Oklahoma City, Oklahoma

  • Investigational Site Number 840011

    Tulsa, Oklahoma

  • Investigational Site Number 840065

    Tulsa, Oklahoma

  • Investigational Site Number 840010

    Bethlehem, Pennsylvania

  • Investigational Site Number 840009

    Duncansville, Pennsylvania

  • Investigational Site Number 840062

    Reading, Pennsylvania

  • Investigational Site Number 840058

    Columbia, South Carolina

  • Investigational Site Number 840016

    North Charleston, South Carolina

  • Investigational Site Number 840025

    Jackson, Tennessee

  • Investigational Site Number 840001

    Dallas, Texas

  • Investigational Site Number 840022

    Dallas, Texas

Showing 40 of 262 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.